Showing 5291-5300 of 5621 results for "".
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o
- Alcon Acquires Fluid-Based IOL Maker PowerVisionhttps://modernod.com/news/alcon-announces-acquisition-of-powervision/2476387/Alcon announced that it has acquired PowerVision for $285 million plus regulatory and milestone payments starting in 2023. PowerVision’s lens design utilizes the eye’s natural accommodating response to transport fluid in the IOL. While most presbyopia-correcting IOLs use a mult
- Nicox Signs Agreement for Zerviate in China for Up to €17 Million in Milestone Payments Plus Royaltieshttps://modernod.com/news/nicox-signs-agreement-for-zerviate-in-china-for-up-to-e17-million-in-milestone-payments-plus-royalties/2476381/Nicox SA and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of all
- Ivantis Announces 24-Month Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-24-month-results-of-landmark-prospective-randomized-comparative-migs-clinical-trial/2476379/Ivantis, developer of the Hydrus Microstent, announced the 24-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study were presented by Thomas Samuelson, MD, President of the American Society of Cataract and Refracti
- Coburn Technologies Introduces New Spin Coater with Dual-Coating Technology, Velocity 2Dhttps://modernod.com/news/coburn-technologies-introduces-new-spin-coater-with-dual-coating-technology-velocity-2d/2476376/Coburn Technologies has introcued the Velocity 2D, the next generation of the Velocity Automated Spin Coater, now designed with dual-coating technology. Derived from the existing platform of the ground-breaking Velocity automated lens coater, the Velocity 2D now offers labs the ability to
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Topcon Introduces the IS-100 Ophthalmic Unithttps://modernod.com/news/topcon-introduces-the-is-100-ophthalmic-unit/2476366/Topcon Medical Systems has announced the launch of the new IS-100 Ophthalmic Unit to the export market. The IS-100 will replace the existing IS-600N model which has been discontinued, and includes several new features that simplifies the installation, enhances its durability and facilitates its u
- Study Results Show NeurOptics’ NPi-200 Pupillometer Provides Early Warning of Neurological Damagehttps://modernod.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/A new study found that NeurOptics’ NPi-200 Pupillometer, which provides an automated assessment of the pupillary light reflex, may signal an early warning of potential delayed cerebral ischemia and enable preemptive escalation of care. The study was published in the Journal of Neurosurgery
- Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimabhttps://modernod.com/news/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/2476355/Roche and Genentech have initiated two large global phase 3 clinical trials in wet age-related macular degeneration (AMD) investigating the bispecific molecule, faricimab. Faricimab is the first bispecific antibody designed specifically for the treatment of retinal eye diseases that simultaneousl
- Eyecare Services Partners Names New CEO and Adds Two Other Executiveshttps://modernod.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/Eyecare Services Partners (ESP) has appointed George Neal as chief executive officer, effective March 4. Mr. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America, according to a